BiondVax Pharmaceuticals (BVXV) Stock Forecast, Price & News

BiondVax Pharmaceuticals (NASDAQ:BVXV) Frequently Asked Questions

Is BiondVax Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BiondVax Pharmaceuticals stock.
View analyst ratings for BiondVax Pharmaceuticals or view top-rated stocks.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 61,600 shares, a decline of 16.4% from the April 30th total of 73,700 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is presently 0.1 days.
View BiondVax Pharmaceuticals' Short Interest.

When is BiondVax Pharmaceuticals' next earnings date?

BiondVax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, June 22nd 2022.
View our earnings forecast for BiondVax Pharmaceuticals.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) posted its earnings results on Monday, March, 28th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.18.
View BiondVax Pharmaceuticals' earnings history.

What price target have analysts set for BVXV?

1 equities research analysts have issued 1 year target prices for BiondVax Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate BiondVax Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 438.5% from the stock's current price.
View analysts' price targets for BiondVax Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are BiondVax Pharmaceuticals' key executives?

BiondVax Pharmaceuticals' management team includes the following people:

• Mr. Amir Reichman M.B.A., M.Sc., CEO & Director (Age 46)
• Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA, Chief Financial Officer (Age 52)
• Mr. Elad Mark B.Sc., Eng., M.B.A., Chief Operating Officer (Age 40)
• Dr. Tamar Ben-Yedidia Ph.D., Chief Scientist (Age 58)
• Mr. Joshua E. Phillipson B.Sc., M.B.A., Director of Bus. Devel. & Investor Relations
• Ms. Moran Ahdout Fruchter L.L.B., Chief of Staff
• Ms. Dalit Weinstein Fischer, Head of Technical R&D

Who are some of BiondVax Pharmaceuticals' key competitors?

Some companies that are related to BiondVax Pharmaceuticals include Orchard Therapeutics (ORTX), Codiak BioSciences (CDAK), Cardiff Oncology (CRDF), MiNK Therapeutics (INKT), Protalix BioTherapeutics (PLX), Protalix BioTherapeutics (PLX), Aligos Therapeutics (ALGS), Entera Bio (ENTX), CASI Pharmaceuticals (CASI), Pluristem Therapeutics (PSTI), PharmaCyte Biotech (PMCB), Xtant Medical (XTNT), AIM ImmunoTech (AIM), IN8bio (INAB) and Evaxion Biotech A/S (EVAX).
View all of BVXV's competitors.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $1.30.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals has a market capitalization of $14.76 million. The company earns $-12.85 million in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does BiondVax Pharmaceuticals have?

BiondVax Pharmaceuticals employs 15 workers across the globe.

What is BiondVax Pharmaceuticals' official website?

The official website for BiondVax Pharmaceuticals is www.biondvax.com.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 9723029302529, via email at [email protected], or via fax at 972-8930-2531.